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Available online xxxxIdarucizumab is an antibody fragmentwhich is used to reverse the anticoagulant effects of dabigatran.We report
on the ﬁrst successful use of idarucizumab before performing an emergency lumbar puncture in a patient on ef-
fective anticoagulation with dabigatran thought to have infective cerebral disease (such as temporal
encephalitis).
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).An85-year-oldmale patientwas admitted to our emergency depart-
ment (ED) with fever (38.6 °C/101.5 °F) and new onset of aphasia at
night in late February 2016. The patient was on dabigatran 110 mg
BID because of non valvular atrial ﬁbrillation (NVAF). In addition, the
patient had also been diagnosed with hypertension, hyperlipidemia
and chronic renal insufﬁciency. The patient was last seenwithout apha-
sia the day before admission. Time of last dabigatran intake was un-
known at the time of presentation in our ED. Neurological status on
admission revealed a severe aphasia (NIHSS [National Institutes of
Health Stroke Scale] = 4). The Glasgow Coma Scale (GCS) was 13 (pa-
tient was confused, disoriented).
Magnetic resonance imaging (MRI) was not available at night. The
emergency computer tomography scan showed no signs of acute cere-
bral ischemia or hemorrhage. The thrombin time (TT) was 55.8 s (nor-
mal b13.0 s) and the activated partial thromboplastin time (aPTT) was
45.3 s (normal range: 26.0–40.0 s). The creatinine clearance was
52 ml/min, the C-reactive protein (CRP) was 18.5 mg/l (normal b5.0 mg/l)
and the leukocyte count was 7.55/nl (normal range: 3.90–10.50/nl).
Differential diagnoses included stroke with unknown onset with ac-
companying infective disease and infective cerebral disease such as
temporal encephalitis (new aphasia, fever and elevated CRP).Wedecid-
ed to perform an emergency lumbar puncture to narrow down differen-
tial diagnosis. Therefore, we ﬁrst injected the patient with 5 g
idarucizumab. Thrombin time (TT) and the activated partial thrombo-
plastin time (aPTT) both rapidly normalized. TT was 10.6 s (normal
b13.0 s) and aPTT was 32.7 s (normal range: 26.0–40.0 s) after
idarucizumab application. Lumbar puncture was performed without
difﬁculties. We did not notice any bleeding during or following the pro-
cedure. Cerebrospinal ﬂuid (CSF) showed very mild pleocytosis.B. Braemswig).
et al, Emergency lumbar pu
rnal of Emergency Medicine (
. This is an open access article under(number of cells: 5/μl; normal range: 0–4/μl). PCR did not show herpes
simplex, varicella zoster or Epstein-Barr virus within CSF.
On the next day, magnetic resonance imaging revealed a subacute
middle cerebral artery infarction. Duplex sonography revealed a high-
grade left-sided proximal internal carotid artery stenosis (90% accord-
ing to NASCET criteria). Additionally, an acute laryngitis was diagnosed.
The patient was given antibiotics because of the laryngitis. Carotid end-
arterectomywas performed because of the high grade stenosis. Follow-
ing surgery, we recommended to continue medical therapy with a
NOAC because of NVAF.
Idarucizumab is a humanized monoclonal antibody fragment (Fab)
indicated in patients treated with dabigatran when reversal of the anti-
coagulant effects of dabigatran is needed for emergency surgery/urgent
procedures or in life-threatening or uncontrolled bleeding [1-3]. For the
ﬁrst time, we report on a patient receiving dabigatran 110 mg BID in
whom idarucizumab was successfully used before performing an emer-
gency lumbar puncture. This adds important information to very recent
case reports describing the use of idarucizumab before intravenous
thrombolysis with recombinant tissue-type plasminogen activator in
stroke patients receiving dabigatran [4,5].
In our report, emergency lumbar puncture was indicated because of
possible infective cerebral disease (aphasia, fever and elevated CRP). In
EDmore thorough history takingwas not possible due to severe aphasia
and lack of relatives to report further details on the onset or dynamics of
the disease. Therefore, we could not determine the time of intake of the
last dabigatran dose. The results of the coagulation tests (aPTT and TT
both increased) suggested effective dabigatran concentration [2]. Appli-
cation of 5 g idarucizumab resulted in prompt normalization of coagula-
tion tests, indicating a successful antagonization of the anticoagulant
effects of dabigatran. Lumbar puncture, which requires normal hemo-
stasis, was performed without difﬁculties or complications in the ED
helping to narrow down differential diagnosis.ncture in a patient receiving dabigatran after antagonization with
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2 T.B. Braemswig et al. / American Journal of Emergency Medicine xxx (2016) xxx–xxxAlternative strategies for this emergency setting included:
(1) Performing MRI/MR-Angiography (MRA)/Computed tomogra-
phy Angiography (CTA), (2) empirical treatment with aciclovir. Be-
cause MRI was not available at night we discussed both performing
CTA and empirical treatment with aciclovir. In both cases, however,
we opted for lumbar puncture because renal insufﬁciency might
have worsened following CTA or aciclovir application. The differ-
ential diagnosis of encephalitis was made unlikely in a timely
manner.
We demonstrated that idarucizumab can be successfully used before
performing an emergency lumbar puncture in a patient on effective
anticoagulation with dabigatran.Disclosure
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